Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/021536external-prioritypatent/WO2000017202A1/en
Application filed by Abbott Gmbh & Co. KgfiledCriticalAbbott Gmbh & Co. Kg
Publication of BG105355ApublicationCriticalpatent/BG105355A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Chemical compounds having the structural formula and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders. 45 claims
BG105355A1998-09-182001-03-164-aminopyrrolopyrimidines as kinase inhibitors
BG105355A
(en)